VivoPower adopts a “DAT 2.0” strategy to gain XRP exposure at 84% off via Ripple equity while earning yield through Flare ...

Our progress developing ABS-201 for androgenetic alopecia is ahead of plan as we expect to initiate a phase 1/2a trial in ...